Standout Papers
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) (2023)
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (2018)
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) (2023)
Immediate Impact
1 from Science/Nature 59 standout
Citing Papers
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Works of Maria Silk being referenced
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
2023 Standout
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Maria Silk | 540 | 189 | 207 | 355 | 17 | 830 | |
| Shizuyo Tsujimura | 529 | 221 | 232 | 281 | 32 | 948 | |
| Christopher Collins | 513 | 185 | 61 | 484 | 24 | 907 | |
| Allen R. Hendricks | 598 | 155 | 79 | 443 | 16 | 905 | |
| Glenn R. Ehresmann | 269 | 104 | 77 | 251 | 13 | 726 | |
| Nobuo Negoro | 377 | 153 | 64 | 407 | 37 | 746 | |
| E. K. Li | 678 | 87 | 55 | 406 | 23 | 898 | |
| Suzanne P. Linn-Rasker | 733 | 289 | 68 | 136 | 14 | 953 | |
| Larissa Lisnevskaia | 492 | 102 | 67 | 385 | 8 | 716 | |
| DJ Wallace | 533 | 133 | 55 | 338 | 23 | 706 | |
| Grainne Kearns | 496 | 141 | 129 | 577 | 19 | 947 |
All Works
Loading papers...